AveXis shares soar after it outlines FDA’s support for a looming pivotal study on SMA
Shares of AveXis $AVXS ripped higher after the market close on Tuesday after the gene therapy biotech outlined the FDA’s acceptance of a
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
